ICP
MCRB icon

Interchange Capital Partners’s Seres Therapeutics MCRB Stock Holding History

Interchange Capital Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-841
Closed -$346K – 175
2021
Q1 		$346K Sell
841
-13
-2% -$5.99K 0.19% 158
2020
Q4 		$418K Buy
+854
New +$500K 0.23% 119

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Interchange Capital Partners's MCRB Position: Q2 2021 in Review

Interchange Capital Partners sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 841 shares — an estimated $346K sold.

Interchange Capital Partners first reported a position in MCRB in Q4 2020 and held it in 2 quarters. The position peaked at $418K in Q4 2020. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • Interchange Capital Partners reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 841 Seres Therapeutics shares in Q2 2021, an estimated $346K.
  • Interchange Capital Partners first reported a position in Seres Therapeutics in Q4 2020 and held it in 2 quarters.
  • Interchange Capital Partners's Seres Therapeutics position peaked at $418K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on Interchange Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.